HighGravityDataInsulet — Aug 7, 2025 release
Fiscal 2025 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001145197-25-000037
Showing in the filing
Drug Delivery
“(80)% - (75)%”
Period
Q3 FY2025
Measure
Company-defined measure
Source
Guidance table
All guidance in this release · 21
U.S. Omnipod Revenue Growth (Constant Curren… for Q3 FY2025
“21% - 24%”
U.S. Omnipod for Q3 FY2025
“21% - 24%”
International Omnipod Revenue Growth (Consta… for Q3 FY2025
“33% - 36%”
International Omnipod for Q3 FY2025
“33% - 36%”
Total Omnipod Revenue Growth (Constant Curre… for Q3 FY2025
“24% - 27%”
Total Omnipod for Q3 FY2025
“24% - 27%”
Drug Delivery Revenue Growth (Constant Curre… for Q3 FY2025
“(80)% - (75)%”
Drug Delivery for Q3 FY2025
“(80)% - (75)%”
Gross Margin for Q3 FY2025
“~71.0%”
Adjusted Operating Margin for Q3 FY2025
“17.0% - 17.5%”
Adjusted Operating Margin for FY2025
“~16.5%”
Total Revenue Growth (Constant Currency) for Q3 FY2025
“22% - 25%”
U.S. Omnipod Revenue Growth (Constant Curren… for FY2025
“22% - 25%”
U.S. Omnipod for FY2025
“22% - 25%”
International Omnipod Revenue Growth (Consta… for FY2025
“34% - 37%”
International Omnipod for FY2025
“34% - 37%”
Drug Delivery Revenue Growth (Constant Curre… for FY2025
“(30)% - (25)%”
Drug Delivery for FY2025
“(30)% - (25)%”
Total Revenue Growth (Constant Currency) for FY2025
“24% - 27%”
Total Omnipod Revenue Growth (Constant Curre… for FY2025
“25% - 28%”
Total Omnipod for FY2025
“25% - 28%”
Exhibit 99.1 · the passage around this item
… earlier in the release
As we scale the Company, I’m confident in our ability to grow and create value for all our stakeholders in the future.” 2025 Outlook: For the quarter ending September 30, 2025 and year ending December 31, 2025, the Company is providing the following guidance (revenue in constant currency): Q3 2025 Guidance FY 2025 Guidance (as of 8/7/2025) FY 2025 Prior Guidance (as of 5/8/2025) U.S. Omnipod 21% - 24% 22% - 25% 18% - 21% International Omnipod 33% - 36% 34% - 37% 27% - 30% Total Omnipod 24% - 27% 25% - 28% 20% - 23% Drug Delivery (80)% - (75)% (30)% - (25)% (35)% - (25)% Total 22% - 25% 24% - 27% 19% - 22% Gross Margin ~71.0% ~71.0% Adjusted Operating Margin 17.0% - 17.5% ~16.5% Conference Call: Insulet will host a conference call at 8:00 a.m. (Eastern Time) on August 7, 2025 to discuss the financial results and outlook. The link to the live call will be available on the Investor Relations section of the Company’s website at investors.insulet.com, “Events and Presentations,” and will be archived for future reference. The live call may also be accessed by dialing (888) 770-7129 for domestic callers or (929) 203-2109 for international callers, passcode 5904836. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automa
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.